Return on investment 2: Evaluating the cost-effectiveness of needle and syringe programs in Australia 2009

This project aimed to: estimate the population benefits of needle and syringe programs (NSPs) on HIV and hepatitis C virus (HCV) related outcomes among injecting drug users (IDUs) in Australia and in each State and Territory over the period from 2000 to 2009; explore changes in the provision of NSPs, populations at risk, and sharing behaviour on these outcomes; and calculate the net present value and future values and cost-effectiveness of NSPs in terms of HIV and HCV infections averted from a health sector (government as third party payer) perspective.

Please click here to view the report.